(NASDAQ: NKTX) Nkarta's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.82%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.32%.
Nkarta's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast NKTX's revenue for 2028 to be $2,824,110,649, with the lowest NKTX revenue forecast at $2,824,110,649, and the highest NKTX revenue forecast at $2,824,110,649. On average, 1 Wall Street analysts forecast NKTX's revenue for 2029 to be $7,890,480,005, with the lowest NKTX revenue forecast at $7,890,480,005, and the highest NKTX revenue forecast at $7,890,480,005.
In 2030, NKTX is forecast to generate $7,601,186,057 in revenue, with the lowest revenue forecast at $1,184,991,152 and the highest revenue forecast at $13,240,679,576.